Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.
Schwarz TF, Hwang SJ, Ylisastigui P, Liu CS, Takazawa K, Yono M, Ervin JE, Andrews CP, Fogarty C, Eckermann T, Collete D, de Heusch M, De Schrevel N, Salaun B, Lambert A, Maréchal C, Olivier A, Nakanwagi P, Lievens M, Hulstrøm V. Schwarz TF, et al. Among authors: takazawa k. J Infect Dis. 2024 Jul 25;230(1):e102-e110. doi: 10.1093/infdis/jiad546. J Infect Dis. 2024. PMID: 39052726 Free PMC article. Clinical Trial.
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group. Papi A, et al. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. N Engl J Med. 2023. PMID: 36791160 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 38099559
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.
Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 Study Group. Ison MG, et al. Clin Infect Dis. 2024 Jun 14;78(6):1732-1744. doi: 10.1093/cid/ciae010. Clin Infect Dis. 2024. PMID: 38253338 Free PMC article. Clinical Trial.
DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
Toyama K, Eto T, Takazawa K, Shimizu S, Nakayama T, Furihata K, Sogawa Y, Kumazaki M, Jonai N, Matsunaga S, Takeshita F, Yoshihara K, Ishizuka H. Toyama K, et al. Among authors: takazawa k. Vaccine. 2023 Aug 31;41(38):5525-5534. doi: 10.1016/j.vaccine.2023.07.012. Epub 2023 Aug 14. Vaccine. 2023. PMID: 37586958 Free article. Clinical Trial.
Long Term Follow-Up Study of a Randomized, Open-Label, Uncontrolled, Phase I/II Study to Assess the Safety and Immunogenicity of Intramuscular and Intradermal Doses of COVID-19 DNA Vaccine (AG0302-COVID19).
Nakagami H, Matsumoto T, Takazawa K, Sekino H, Matsuoka O, Inoue S, Furuie H, Morishita R. Nakagami H, et al. Among authors: takazawa k. Vaccines (Basel). 2023 Sep 28;11(10):1535. doi: 10.3390/vaccines11101535. Vaccines (Basel). 2023. PMID: 37896939 Free PMC article.
Temporal effects of lascufloxacin on human gut and salivary microbiota: Analysis using next-generation sequencing method.
Mukuda K, Inoue R, Takata M, Takazawa K, Noma H, Morishima S, Oda M, Ma'arif AS, Endo Y, Sunada H, Doi A, Matsuda R, Nishikawa Y, Okada K, Kitaura T, Nakamoto M, Yamasaki A, Chikumi H. Mukuda K, et al. Among authors: takazawa k. J Infect Chemother. 2024 Jul 30:S1341-321X(24)00206-X. doi: 10.1016/j.jiac.2024.07.023. Online ahead of print. J Infect Chemother. 2024. PMID: 39089446
Artificial Intelligence-Generated Draft Replies to Patient Inbox Messages.
Garcia P, Ma SP, Shah S, Smith M, Jeong Y, Devon-Sand A, Tai-Seale M, Takazawa K, Clutter D, Vogt K, Lugtu C, Rojo M, Lin S, Shanafelt T, Pfeffer MA, Sharp C. Garcia P, et al. Among authors: takazawa k. JAMA Netw Open. 2024 Mar 4;7(3):e243201. doi: 10.1001/jamanetworkopen.2024.3201. JAMA Netw Open. 2024. PMID: 38506805 Free PMC article.
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.
Curran D, Matthews S, Cabrera ES, Pérez SN, Breva LP, Rämet M, Helman L, Park DW, Schwarz TF, Melendez IMG, Schaefer A, Roy N, Stephan B, Molnar D, Kostanyan L, Powers JH 3rd, Hulstrøm V; Members of the AReSVi‐006 Study Group. Curran D, et al. Influenza Other Respir Viruses. 2024 Feb 3;18(2):e13236. doi: 10.1111/irv.13236. eCollection 2024 Feb. Influenza Other Respir Viruses. 2024. PMID: 38314063 Free PMC article. Clinical Trial.
224 results